The company has received the manufacturing and marketing approval from Drugs Controller General of India (DCGI) to launch favipiravir.
Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation, Glenmark Pharmaceuticals said in a statement.Drug firm Glenmark Pharmaceuticals on Friday said it has received approval from the Indian drug regulator to launch oral antiviral drug favipiravir for treatment of mild to moderate COVID-19 patients in the country.
It is for restricted emergency use in India. Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation, Glenmark Pharmaceuticals said in a statement.
The company has received the manufacturing and marketing approval from Drugs Controller General of India (DCGI) to launch favipiravir for the treatment of mild to moderate COVID-19 patients, it said.
“This approval has been granted based on evaluation of data and in consultation with the Subject Expert Committee, as part of accelerated approval process, considering the emergency situation and unmet medical need of the COVID-19 outbreak,” Glenmark said.
Shares of Glenmark Pharmaceuticals closed at Rs 409.10 per scrip on the BSE, up 0.93 per cent from its previous close.
Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.
Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.
